Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Gainers
Why Blackmores, Class, Mesoblast, & St Barbara shares raced higher today
Share Gainers
Why Mesoblast, New Hope, Pilbara Minerals, & Syrah shares charged higher today
Share Market News
Paradigm share price tanks despite positive clinical trial update
Share Market News
Why the Mesoblast share price is going nuts today
Share Gainers
Why iSignthis, Leigh Creek, Mesoblast, & Santos shares charged higher
Share Gainers
Mesoblast share price rockets 17% higher on Grünenthal partnership news
Share Market News
Opthea share price lifts on clinical trial update: Is it a spec buy?
Share Market News
Mesoblast share price edges higher on quarterly update
Share Market News
Biotech speccy Paradigm is being tipped for the big time
Share Market News
High profile fundie warns these 10 ASX shares have "bubble" valuations
Share Market News
Telix Pharmaceuticals just boasted it's one step closer to getting a cancer treatment approved
Share Market News
Is the Starpharma share price a buy?
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
